A
Atara Biotherapeutics, Inc. (ATRA)
NMS – Real vaqt narxi. Valyuta: USD
9.81
+1.03 (11.73%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.40
-0.41 (-4.18%)
Bozor oldidan: May 13, 2026, 4:11 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
9.81
+1.03 (11.73%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.40
-0.41 (-4.18%)
Bozor oldidan: May 13, 2026, 4:11 AM EDT
Atara Biotherapeutics, Inc. Qo'shma Shtatlar va xalqaro miqyosda saraton va otoimmunitet kasalliklari bilan og'rigan bemorlar uchun transformativ terapiyalarni ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsuloti Tab-cel (tabelecleucel) hisoblanadi, bu T-hujayrali immunoterapiya dasturi bo'lib, u transplantatsiyadan keyingi limfoproliferativ kasallikni, shuningdek, boshqa EBV bilan bog'liq kasalliklarni davolash uchun 3-bosqichli klinik sinovlarda. Kompaniya, shuningdek, B-hujayrali o'smalar va otoimmunitet kasalliklariga qarshi CD19ni nishonga olgan ATA3219, allogen CAR Tni ishlab chiqadi. Kompaniya Memorial Sloan Kettering Cancer Center va Queensland Medical Research Institute Kengashi bilan tadqiqot hamkorligi shartnomalariga ega. Atara Biotherapeutics, Inc. 2012-yilda tashkil etilgan va uning bosh qarorgohi Thousand Oaks, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Alex Chapman | Vice President of Corporate Communications & Investor Relations |
| Dr. Anhco Nguyen Ph.D. | President, CEO & Director |
| Mr. Jim Sesic | Senior Vice President of Regulatory Affairs |
| Mr. John Chao | Head of Legal |
| Ms. Yanina Grant-Huerta | Chief Accounting Officer & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | atra-20260507.htm |
| 2026-05-01 | 8-K | atra-20260430.htm |
| 2026-04-24 | DEFA14A | atra-2026-defa14a.htm |
| 2026-04-24 | DEF 14A | atra-20260424.htm |
| 2026-03-17 | S-3 | d100379ds3.htm |
| 2026-03-16 | 10-K | atra-20251231.htm |
| 2026-03-12 | 8-K | atra-20260312.htm |
| 2026-03-03 | 8-K | d121575d8k.htm |
| 2026-02-23 | 8-K | d105335d8k.htm |
| 2026-01-12 | 8-K | d34257d8k.htm |